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Abstract 
Alpha-dystroglycanopathies are a group of progressive and untreatable neuromuscular disorders, due to aberrant alpha-dystroglycan glyco- 
sylation. We describe the effects of a short-term cycle of corticosteroid therapy in a 9-year-old boy, affected by an alpha-dystroglycanopathy 
due to GMPPB gene mutations. The patient was affected by a congenital progressive muscular dystrophy since the first month of life, associ- 
ated with psychomotor delay, seizures, and congenital bilateral cataracts. Despite physical therapy he had a progressive motor impairment. At 
the age of 9 years, he was treated with 0.75 mg/kg/day of prednisone for 3 months and showed improvements in muscle strength and function 
scores and creatine kinase reduction. When steroid therapy was discontinued he showed again clinical and biochemical deterioration. These 
data suggest that corticosteroid may be considered as a treatment for patients with alpha-dystroglycanopathies due to GMPPB mutations. 
© 2018 Elsevier B.V. All rights reserved. 
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p  1. Introduction 
Alpha-dystroglycanopathies are a genetically and clinically
heterogeneous group of neuromuscular disorders, due to aber-
rant alpha-dystroglycan glycosylation. Dystroglycan is a pro-
tein complex composed of alpha and beta subunits, and is
an essential link between the extracellular matrix and the
actin-associated cytoskeleton, especially in muscle tissues.
This complex plays a fundamental role in the development
and maintenance of basement membranes, in neuronal mi-
gration, and in neuromuscular junction formation. Alpha-
dystroglycan posttranslational glycosylation is critical for its∗ Corresponding author at: Giancarlo Parenti, Department of Translational 
Medical Sciences, Section of Pediatrics, Federico II University, Via S. Pansini 
5, Naples 80131, Italy and Telethon Institute of Genetics and Medicine, Via 
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0960-8966/© 2018 Elsevier B.V. All rights reserved. unction [1] . To date, mutations in 21 genes have been associ-
ted with defective alpha-dystroglycan glycosylation. Among
hese, GMPPB encodes an enzyme (GDP-mannose pyrophos-
horylase B) that catalyses the formation of GDP-mannose,
equired for O-mannosylation of alpha-dystroglycan. GMPPB
utations have been described so far in about 50 cases. The
henotypic spectrum is broad, including severe congenital
uscular dystrophy (CMD) associated with brain and eye
bnormalities and intellectual disability (i.e. Walker–Warburg
yndrome, muscle-eye-brain disease, and Fukuyama congeni-
al muscular dystrophy), severe congenital muscular dystro-
hy with absent or mild brain involvement (MDC1C and
DC1D), milder forms of late onset limb-girdle muscular
ystrophies (LGMD2I and LGMD2K) [2] , and a congeni-
al myasthenic syndrome [3] . The disease course is generally
rogressive. Although in the myasthenic presentations some
enefits have been obtained with pyridostigmine and salbuta-
ol, to date there is no effective therapy available for other
S. Fecarotta et al. / Neuromuscular Disorders 28 (2018) 956–960 957 
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ihenotypes [1] . Here, we describe the effects of a short-term
ycle of prednisone therapy in a patient affected by GMPPB
lpha-dystroglycanopathy. 
. Case report 
The patient, a 9 years and 6 months old boy of non-
onsanguineous parents, was first referred to our hospital
t the age of 6 months because of microcephaly, hypoto-
ia, elevated serum creatine kinase (CK), psychomotor de-
ay, seizures, and congenital bilateral cataracts. At the age
f 7 months cataracts were treated surgically, with residual
odest increase in eye pressure. The diagnosis of alpha-
ystroglycanopathy was based on muscle histology, per-
ormed at the age of 4 years, showing a dystrophic pattern
ith reduced alpha-dystroglycan, and on the molecular analy-
is of the GMPPB gene that showed compound heterozygosity
or the p.Q234 ∗ and p.T153I mutations. 
During follow-up psychomotor delay became progressively 
ore evident, with independent ambulation acquired at 4
ears of age. Since the age of 8 years, the patient presented a
apid deterioration in functional abilities, and at the age of 9
ears he could sit and hold up his head unsupported only for
hort periods; he was able to stand and walk only for short
istances; he could not roll, climb or descend stairs, and was
nable to rise from the floor or stand up from a chair with-
ut support. On physical examination, he showed axial andig. 1. Changes in serum CK levels before, during and after corticosteroid treatm
erum CK values in the last 5 years before corticosteroid treatment were elevate
f oral steroids for intercurrent respiratory infection (405 U/L). Before corticoste
0% during the therapy (range 324–464 U/L). Reduction was statistically significa
ncreased again. roximal weakness with a predominant involvement of the
ower limb. He had mild intellectual disability (IQ = 10–25
ercentile with Raven matrix). 
At two different occasions, the parents reported on tran-
ient improvements of muscle strength and motor activity af-
er the administration of oral steroids for intercurrent respi-
atory infections. On one of these occasions a reduction of
erum CK levels to 405 U/L was also documented, compared
o average CK values in the last 5 years of 1650 U/l (range
14–5082 U/L). Based on this information and after approval
y the ethics committee and informed consent from par-
nts, when the patient was 9 years old we started a 3-month
rial with 0.75 mg/kg/day oral prednisone, according to the
reatment protocol for Duchenne muscular dystrophy (DMD)
4] . The patient was evaluated monthly by clinical examina-
ion, laboratory tests, muscle strength scale (Medical Research
ouncil—MRC) and motor function scales (motor function
easure—MFM, Vignos and Brooke), already validated for
ther muscular dystrophies such as DMD [5,6] . Despite the
resence of mild intellectual disability, the patient was collab-
rative and compliant with all tests. During treatment serum
K significantly decreased ( Fig. 1 , Supplementary Table S1)
nd the patient showed improvements of motor function eval-
ated by Vignos and Brooke rating scale ( Fig. 2 a, Supple-
entary Table S2a) and by MFM ( Fig. 2 b, Supplementary
able S2b) and of muscle strength evaluated by MRC ( Fig. 3 ,
upplementary Table S3). At the end of the trial he had re-ent. 
d (range 814–5082 U/L, average 1650 U/L), except after the administration 
roid treatment, serum CK level was 990 U/L, and decreased by more than 
nt ( p = 0.002 with Mann–Witney test). After prednisone tapering CK levels 
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Fig. 2. Changes in motor function scores before, during and after corticosteroid treatment. 
(a) Values of Vignos and Brooke score. (b) Motor function measure (MFM) scale. Vignos score and MFM showed an improvement, especially for lower 
limbs, during corticosteroid treatment and a worsening after their discontinuation. Brooke score remained unchanged. 
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R  gained the ability to stand and walk independently, although
only for short distances, and showed improved trunk and
head control; he could rise his arms above his head, roll and
rise from sitting to standing position with minimal support.
Possible undesired effects (hyperglycemia, hypertension, bone
loss, excessive weight gain) were closely monitored. Only a
modest weight gain (2 kg) was observed. The patient did not
experience infections, sleep/behavior or gastrointestinal prob-
lems. Cardiac examination remained normal. On ophthalmicxamination, however, a further increase of intraocular pres-
ure was documented, thus prednisone therapy was gradu-
lly tapered ( −2.5 mg every 2 weeks) and discontinued over
 months. Prednisone decalage and discontinuation resulted in
esumption of disease manifestation, with deterioration of
uscle strength ( Fig. 3 , Supplementary Table S3) and a drop
n function score ( Fig. 2 a, b, Supplementary Table S2a, b).
erum CK levels increased ( Fig. 1 , Supplementary Table S1).
emarkably, already after 1 month of prednisone decalage, at
S. Fecarotta et al. / Neuromuscular Disorders 28 (2018) 956–960 959 
Fig. 3. Changes in muscular strength score before, during and after corticos- 
teroid treatment. 
Medical Research Council (MRC) scale showed an improvement during cor- 
ticosteroid treatment and a worsening after their discontinuation. 
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  dosage of 0.5 mg/kg/day, the patient had lost the ability to
alk even with support and to rise from sitting to a standing
osition. At the end of decalage he lost the ability to stand
ithout support and he could control head and trunk in the
itting position only for a few minutes. 
. Discussion 
Corticosteroid treatment is known to slow the decline in
uscle strength and function in DMD, in which it is now
ne of the mainstays in the treatment [4] . The mechanisms
nderlying its effect are not completely clear, likely due to an
nabolic effect on myoblast proliferation and muscle regener-
tion, and to the ability to reduce muscle necrosis and inflam-
ation [7–10] . Efficacy of corticosteroid treatment in muscu-
ar dystrophies other than DMD has not been formally proven.
 few anecdotal reports indicated that corticosteroid treat-
ent also improved motor abilities in dystroglycanopathies,
uch as FKRP (Fukutin-related protein) muscular dystrophy.
 study in a murine experimental model of LGMD 2I car-
ying the FKRP p.P448L mutation demonstrated that corti-
osteroids, alone or in combination with alendronate, enhance
unctionally glycosylated alpha-dystroglycan, improve muscle 
athology and alleviate the dystrophic phenotype [11] . God-
rey et al. and Darin et al. reported on five LGMD patients
ith FKRP mutations, erroneously diagnosed as affected by
olymyositis (two cases) or DMD (three cases) and treated
ith steroids, that showed a remarkable clinical response to
his treatment [ 12 , 13 ]. 
Based on these literature data we tested the effects of pred-
isone in our patient, using the same therapeutic regimen that
s in use for DMD [4] . The results of this short-term trial were
ncouraging. 
On prednisone treatment our patient showed improvements
n tests that evaluate motor function, with regain of some
otor skills, and muscle strength, and significant decreasen CK levels. Improvements in muscle strength and func-
ion were more evident in the lower limbs, probably because
hey were initially more compromised. The resumed rapid
eterioration of muscle strength and motor functions expe-
ienced by the patients when prednisone was discontinued
urther supports the efficacy of corticosteroid treatment. Al-
eit anecdotal and based on a single case report, our experi-
nce suggests that corticosteroids may be considered to treat
ther patients with alpha-dystroglycanopathies due to GMPPB
utations and with rapidly progressive impairment of motor
unction. 
This research did not receive any specific grant from fund-
ng agencies in the public, commercial, or not-for-profit sec-
ors. 
upplementary materials 
Supplementary material associated with this article can be
ound, in the online version, at doi: 10.1016/j.nmd.2018.07.
01 . 
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